---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-26-000370"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:06:47.224454+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Immunic appoints Jon Congleton, Mineralys CEO and ex-Teva exec, to Board

## Summary
- Jon Congleton appointed to Board as Class II director effective March 27, 2026; Board size increased from 8 to 9.
- Congleton will chair Compensation Committee; received initial grant of options for 500,000 shares vesting over 3 years.
- Congleton brings nearly 40 years of biopharma experience; currently CEO of Mineralys Therapeutics.
- He previously led the U.S. launch of Copaxone at Teva and held senior roles at Impel NeuroPharma and Nivalis Therapeutics.
- Appointment supports Immunic's transition to commercial stage for MS drug vidofludimus calcium.

## SEC filing metadata
- accession: 0001193805-26-000370
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000370/0001193805-26-000370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380526000370/e665296_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-26-000370
- JSON: https://secwatch.observer/filing/0001193805-26-000370.json
- Plain text: https://secwatch.observer/filing/0001193805-26-000370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.